Pluri Inc. (TLV:PLUR)

Market Cap	87.59M
Revenue (ttm)	4.50M
Net Income (ttm)	-76.09M
Shares Out	n/a
EPS (ttm)	-12.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,846
Average Volume	7,035
Open	1,140.00
Previous Close	1,156.00
Day's Range	1,080.00 - 1,142.00
52-Week Range	1,080.00 - 2,345.00
Beta	n/a
RSI	18.11
Earnings Date	Nov 13, 2025

About Pluri

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 142
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: PLUR

Financial Performance

In 2025, Pluri's revenue was $1.34 million, an increase of 309.82% compared to the previous year's $326,000. Losses were -$22.58 million, 8.11% more than in 2024.

Financial numbers in USD